Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Lanreotide | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Lanreotide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Lanreotide | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Lanreotide | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | Lanreotide | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Lanreotide | hsa00220 | Arginine biosynthesis | 5.12E-03 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Lanreotide | hsa00250 | Alanine, aspartate and glutamate metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | | Lanreotide | hsa00270 | Cysteine and methionine metabolism | 1.92E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | | Lanreotide | hsa00310 | Lysine degradation | 2.34E-03 | 3 | Q96KQ7, Q02809, P51648 | EHMT2, PLOD1, ALDH3A2 | More | | Lanreotide | hsa00350 | Tyrosine metabolism | 3.40E-02 | 1 | P28332 | ADH6 | More | | Lanreotide | hsa00471 | D-Glutamine and D-glutamate metabolism | 1.65E-02 | 1 | P49448 | GLUD2 | More | | Lanreotide | hsa00500 | Starch and sucrose metabolism | 1.53E-05 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Lanreotide | hsa00562 | Inositol phosphate metabolism | 2.00E-02 | 4 | P27987, P19174, P42338, Q02252 | ITPKB, PLCG1, PIK3CB, ALDH6A1 | More | | Lanreotide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Lanreotide | hsa00591 | Linoleic acid metabolism | 3.18E-02 | 1 | P11712 | CYP2C9 | More | | Lanreotide | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.89E-04 | 2 | P40925, P15104 | MDH1, GLUL | More | | Lanreotide | hsa00730 | Thiamine metabolism | 1.81E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Lanreotide | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Lanreotide | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Lanreotide | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | Lanreotide | hsa00910 | Nitrogen metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | | Lanreotide | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.94E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Lanreotide | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.50E-02 | 1 | P28332 | ADH6 | More | | Lanreotide | hsa00982 | Drug metabolism - cytochrome P450 | 4.50E-02 | 1 | P28332 | ADH6 | More | | Lanreotide | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Lanreotide | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Lanreotide | hsa02010 | ABC transporters | 1.66E-04 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Lanreotide | hsa03008 | Ribosome biogenesis in eukaryotes | 2.52E-02 | 3 | P78345, O15381, Q9GZY0 | RPP38, NVL, NXF2; NXF2B | More | | Lanreotide | hsa03013 | RNA transport | 9.68E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Lanreotide | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Lanreotide | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Lanreotide | hsa03040 | Spliceosome | 4.12E-07 | 15 | Q14562, O43143, O60508, Q99633, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, Q9UMS4, P11142, Q9Y2W2, O75643 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PRPF19, HSPA8, WBP11, ASCC3L1 | More | | Lanreotide | hsa03060 | Protein export | 3.28E-02 | 1 | Q15070 | OXA1L | More | | Lanreotide | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Lanreotide | hsa04010 | MAPK signaling pathway | 4.76E-02 | 5 | Q15283, P21860, Q12933, P01584, O14944 | RASA2, ERBB3, TRAF2, IL1B, EREG | More | | Lanreotide | hsa04012 | ErbB signaling pathway | 2.00E-02 | 4 | P16333, P17252, P19174, P42338 | NCK1, PRKCA, PLCG1, PIK3CB | More | | Lanreotide | hsa04014 | Ras signaling pathway | 7.71E-04 | 10 | P42338, P20827, P49767, Q13009, P17252, P14921, P0DP23, P62873, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, PRKCA, ETS1, CALM1, GNB1, GNG10, PLCG1 | More | | Lanreotide | hsa04015 | Rap1 signaling pathway | 4.93E-04 | 10 | P20827, P49767, P63261, P11215, P25116, Q13009, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, ACTG1, ITGAM, F2R, TIAM1, PIK3CB, CALM1, PRKCA, PLCG1 | More | | Lanreotide | hsa04020 | Calcium signaling pathway | 2.93E-05 | 13 | P27987, Q96DU7, Q08828, Q16566, Q13557, P17252, P21860, O15399, P19174, P25116, P0DP23, P23634, P49767 | ITPKB, ITPKC, ADCY1, CAMK4, CAMK2D, PRKCA, ERBB3, GRIN2D, PLCG1, F2R, CALM1, ATP2B4, VEGFC | More | | Lanreotide | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Lanreotide | hsa04024 | cAMP signaling pathway | 3.62E-03 | 9 | P42338, P0DP23, P23634, Q16566, Q13370, O15399, P25963, P25116, Q13009 | PIK3CB, CALM1, ATP2B4, CAMK4, PDE3B, GRIN2D, NFKBIA, F2R, TIAM1 | More | | Lanreotide | hsa04060 | Cytokine-cytokine receptor interaction | 3.21E-04 | 16 | P14784, P27930, P14778, P26842, Q06643, Q9UHF4, Q13651, P16871, P25024, Q9UBD3, P47992, P02775, P09341, P32248, P51684, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL20RA, IL10RA, IL7R, CXCR1, XCL2, XCL1, PPBP, CXCL1, CCR7, CCR6, CD4 | More | | Lanreotide | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.92E-05 | 10 | P51684, P32248, P09341, P25024, P02775, P47992, Q9UBD3, Q13651, P14784, Q9UHF4 | CCR6, CCR7, CXCL1, CXCR1, PPBP, XCL1, XCL2, IL10RA, IL2RB, IL20RA | More | | Lanreotide | hsa04062 | Chemokine signaling pathway | 4.21E-06 | 19 | P25024, P25025, P09341, P47992, Q9UBD3, P07948, P42338, P19174, P62873, P63218, P50151, P43250, P49407, Q08881, Q13009, P14598, P42224, P25963, P49841 | CXCR1, CXCR2, CXCL1, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, ARRB1, ITK, TIAM1, NCF1, STAT1, NFKBIA, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.779 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | P06239 | LCK | Tyrosine-protein kinase Lck | P47992 | XCL1 | Lymphotactin | 0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | 0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.728 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | P06239 | LCK | Tyrosine-protein kinase Lck | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.71 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P43250 | GRK6 | G protein-coupled receptor kinase 6 | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P43250 | GRK6 | G protein-coupled receptor kinase 6 | -0.702 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | -0.792 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14598 | NCF1 | Neutrophil cytosol factor 1 | 0.908 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Lanreotide | hsa04064 | NF-kappa B signaling pathway | 7.24E-03 | 8 | O00463, P14778, Q04759, P07948, P06239, P24522, P09341, Q06643 | TRAF5, IL1R1, PRKCQ, LYN, LCK, GADD45A, CXCL1, LTB | More | | Lanreotide | hsa04066 | HIF-1 signaling pathway | 3.40E-02 | 3 | Q09472, P07195, P10415 | EP300, LDHB, BCL2 | More | | Lanreotide | hsa04070 | Phosphatidylinositol signaling system | 3.29E-03 | 6 | P19174, P0DP23, P42338, P23743, P27987, P17252 | PLCG1, CALM1, PIK3CB, DGKA, ITPKB, PRKCA | More | | Lanreotide | hsa04071 | Sphingolipid signaling pathway | 2.56E-05 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Lanreotide | hsa04080 | Neuroactive ligand-receptor interaction | 4.15E-02 | 2 | Q01726, P41968 | MC1R, MC3R | More | | Lanreotide | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UJX4, O60566, Q09472, P24522, P04637, P49918 | ANAPC5, BUB1B, EP300, GADD45A, TP53, CDKN1C | More | | Lanreotide | hsa04144 | Endocytosis | 2.81E-02 | 6 | Q13191, P11142, P25024, P43250, P14784, Q9Y5X3 | CBLB, HSPA8, CXCR1, GRK6, IL2RB, SNX5 | More | | Lanreotide | hsa04145 | Phagosome | 1.06E-03 | 11 | O75015, P63261, Q15080, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | FCGR3B, ACTG1, NCF4, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | Lanreotide | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Lanreotide | hsa04151 | PI3K-Akt signaling pathway | 5.43E-04 | 19 | P62753, P42338, O43521, P27348, P20827, P49767, P08238, Q8WYR1, P62873, P50151, P16144, O15335, Q13751, P14784, P01568, P18848, P17252, O00141, Q6ZUJ8 | RPS6, PIK3CB, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNB1, GNG10, ITGB4, CHAD, LAMB3, IL2RB, IFNA21, ATF4, PRKCA, SGK, PIK3AP1 | More | | Lanreotide | hsa04152 | AMPK signaling pathway | 2.34E-02 | 2 | Q96EB6, P36956 | SIRT1, SREBF1 | More | | Lanreotide | hsa04210 | Apoptosis | 2.44E-04 | 10 | P04637, P10415, O75460, P24522, Q13077, O43521, P43234, Q9UBR2, P18848, Q14643 | TP53, BCL2, ERN1, GADD45A, TRAF1, BCL2L11, CTSO, CTSZ, ATF4, ITPR1 | More | | Lanreotide | hsa04217 | Necroptosis | 9.75E-04 | 11 | P01568, Q13489, P42224, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q9H444, O43633 | IFNA21, BIRC3, STAT1, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, CHMP4B, CHMP2A | More | | Lanreotide | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Lanreotide | hsa04360 | Axon guidance | 2.13E-03 | 7 | P16333, P20827, O95631, P17252, P42338, P23528, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, CFL1, PLCG1 | More | | Lanreotide | hsa04370 | VEGF signaling pathway | 7.68E-03 | 3 | P19174, P42338, P17252 | PLCG1, PIK3CB, PRKCA | More | | Lanreotide | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | | Lanreotide | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | Lanreotide | hsa04510 | Focal adhesion | 7.88E-04 | 11 | P16144, O75369, P42338, Q15942, P17252, O15335, Q13751, Q13489, P10415, P49767, P63261 | ITGB4, FLNB, PIK3CB, ZYX, PRKCA, CHAD, LAMB3, BIRC3, BCL2, VEGFC, ACTG1 | More | | Lanreotide | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Lanreotide | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | Lanreotide | hsa04610 | Complement and coagulation cascades | 4.27E-06 | 1 | P0C0L4 | C4A | More | | Lanreotide | hsa04612 | Antigen processing and presentation | 4.45E-05 | 9 | P13765, P48382, P01730, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, CD4, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Lanreotide | hsa04613 | Neutrophil extracellular trap formation | 8.60E-07 | 22 | P17252, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P04908, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q15722 | LTB4R | Leukotriene B4 receptor 1 | P17252 | PRKCA | Protein kinase C alpha type | -0.757 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P11215 | ITGAM | Integrin alpha-M | 0.734 | P22748 | CA4 | Carbonic anhydrase 4 | O60603 | TLR2 | Toll-like receptor 2 | 0.919 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.942 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.867 | P22748 | CA4 | Carbonic anhydrase 4 | P05164 | MPO | Myeloperoxidase | 0.826 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P05164 | MPO | Myeloperoxidase | 0.805 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P05164 | MPO | Myeloperoxidase | 0.711 | P22748 | CA4 | Carbonic anhydrase 4 | P08246 | ELA2 | Neutrophil elastase | 0.921 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.846 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.703 | P22748 | CA4 | Carbonic anhydrase 4 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.856 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.799 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.825 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.742 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q92769 | HDAC2 | Histone deacetylase 2 | -0.746 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P04908 | H2AC4; H2AC8 | Histone H2A type 1-B/E | 0.734 | P22748 | CA4 | Carbonic anhydrase 4 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.866 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.833 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.737 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.753 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.753 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | O60814 | H2BC12 | Histone H2B type 1-K | 0.793 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.913 | P22748 | CA4 | Carbonic anhydrase 4 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.951 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.918 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.764 | P22748 | CA4 | Carbonic anhydrase 4 | P20160 | AZU1 | Azurocidin | 0.747 | P22748 | CA4 | Carbonic anhydrase 4 | P08311 | CTSG | Cathepsin G | 0.717 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08311 | CTSG | Cathepsin G | 0.709 | P22748 | CA4 | Carbonic anhydrase 4 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.737 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | P22748 | CA4 | Carbonic anhydrase 4 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.826 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.875 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 1 | P22748 | CA4 | Carbonic anhydrase 4 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.895 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.888 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.842 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | O43315 | AQP9 | Aquaporin-9 | -0.764 | P22748 | CA4 | Carbonic anhydrase 4 | O43315 | AQP9 | Aquaporin-9 | 0.771 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O43315 | AQP9 | Aquaporin-9 | 0.79 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O43315 | AQP9 | Aquaporin-9 | 0.915 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.744 | P22748 | CA4 | Carbonic anhydrase 4 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.767 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.721 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 |
| Lanreotide | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Lanreotide | hsa04623 | Cytosolic DNA-sensing pathway | 4.57E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Lanreotide | hsa04625 | C-type lectin receptor signaling pathway | 5.58E-03 | 6 | Q9ULY5, P20749, Q14643, P01375, Q13191, Q16539 | CLEC4E, BCL3, ITPR1, TNF, CBLB, MAPK14 | More | | Lanreotide | hsa04640 | Hematopoietic cell lineage | 3.33E-05 | 13 | P13612, P14778, P27930, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF | More | | Lanreotide | hsa04650 | Natural killer cell mediated cytotoxicity | 7.51E-08 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O14931, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.809 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.81 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.856 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.879 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.893 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.838 |
| Lanreotide | hsa04657 | IL-17 signaling pathway | 2.21E-04 | 8 | O00463, Q16539, P49841, P09341, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, ANAPC5, LCN2, TNF | More | | Lanreotide | hsa04658 | Th1 and Th2 cell differentiation | 7.40E-09 | 13 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.768 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.855 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
| Lanreotide | hsa04659 | Th17 cell differentiation | 1.14E-08 | 18 | P25963, Q04759, Q16539, P19174, P01730, P06239, P42224, P14784, P13765, P14778, P40189, Q9UL17, P23771, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, IL6ST, TBX21, GATA3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.865 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.73 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.762 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.748 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.861 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.767 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.729 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.802 | P07948 | LYN | Tyrosine-protein kinase Lyn | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.782 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 |
| Lanreotide | hsa04660 | T cell receptor signaling pathway | 2.50E-07 | 13 | P01375, Q04759, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01375 | TNF | Tumor necrosis factor | 0.774 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q04759 | PRKCQ | Protein kinase C theta type | -0.762 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.806 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.812 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.77 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.816 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.816 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.833 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.781 |
| Lanreotide | hsa04662 | B cell receptor signaling pathway | 4.07E-02 | 4 | P42338, P60033, P07948, Q8N149 | PIK3CB, CD81, LYN, LILRA2 | More | | Lanreotide | hsa04664 | Fc epsilon RI signaling pathway | 1.91E-03 | 7 | P01375, Q16539, P42338, P17252, Q9UQC2, P19174, P09917 | TNF, MAPK14, PIK3CB, PRKCA, GAB2, PLCG1, ALOX5 | More | | Lanreotide | hsa04666 | Fc gamma R-mediated phagocytosis | 8.08E-03 | 5 | P42338, P19174, P23528, P14598, P17252 | PIK3CB, PLCG1, CFL1, NCF1, PRKCA | More | | Lanreotide | hsa04668 | TNF signaling pathway | 6.21E-05 | 11 | P01375, Q12933, O00463, Q16539, Q99941, P18848, P01584, P20749, P14780, P20333, O95429 | TNF, TRAF2, TRAF5, MAPK14, CREBL1, ATF4, IL1B, BCL3, MMP9, TNFRSF1B, BAG4 | More | | Lanreotide | hsa04713 | Circadian entrainment | 1.43E-03 | 8 | O15399, P0DP23, Q13557, Q02153, P17252, P62873, P50151, Q08828 | GRIN2D, CALM1, CAMK2D, GUCY1B3, PRKCA, GNB1, GNG10, ADCY1 | More | | Lanreotide | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Lanreotide | hsa04720 | Long-term potentiation | 2.74E-03 | 4 | P17252, Q16566, P0DP23, O15399 | PRKCA, CAMK4, CALM1, GRIN2D | More | | Lanreotide | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | Lanreotide | hsa04724 | Glutamatergic synapse | 4.68E-04 | 6 | O15399, P17252, P62873, P63218, P50151, P15104 | GRIN2D, PRKCA, GNB1, GNG5, GNG10, GLUL | More | | Lanreotide | hsa04725 | Cholinergic synapse | 4.26E-02 | 4 | P17252, P62873, P50151, P42338 | PRKCA, GNB1, GNG10, PIK3CB | More | | Lanreotide | hsa04726 | Serotonergic synapse | 2.54E-02 | 5 | P17252, P62873, P50151, P33260, P09917 | PRKCA, GNB1, GNG10, CYP2C18, ALOX5 | More | | Lanreotide | hsa04727 | GABAergic synapse | 1.30E-03 | 5 | P62873, P63218, P50151, P15104, P17252 | GNB1, GNG5, GNG10, GLUL, PRKCA | More | | Lanreotide | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Lanreotide | hsa04744 | Phototransduction | 1.67E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Lanreotide | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.25E-02 | 3 | P01584, Q08828, Q13557 | IL1B, ADCY1, CAMK2D | More | | Lanreotide | hsa04911 | Insulin secretion | 2.23E-02 | 3 | Q08828, Q99941, Q13557 | ADCY1, CREBL1, CAMK2D | More | | Lanreotide | hsa04912 | GnRH signaling pathway | 4.49E-04 | 5 | P17252, Q16539, Q9Y6R4, Q14643, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, PRKACB | More | | Lanreotide | hsa04914 | Progesterone-mediated oocyte maturation | 1.24E-02 | 5 | P42338, Q13370, Q9UJX4, P30304, P08238 | PIK3CB, PDE3B, ANAPC5, CDC25A, HSP90AB1 | More | | Lanreotide | hsa04916 | Melanogenesis | 2.46E-03 | 5 | P0DP23, Q9UJU2, P17252, P49841, Q01726 | CALM1, LEF1, PRKCA, GSK3B, MC1R | More | | Lanreotide | hsa04920 | Adipocytokine signaling pathway | 4.72E-02 | 4 | P33121, Q04759, Q9Y4H2, P01375 | ACSL1, PRKCQ, IRS2, TNF | More | | Lanreotide | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Lanreotide | hsa04925 | Aldosterone synthesis and secretion | 7.20E-03 | 4 | P0DP23, P17252, Q16566, P23634 | CALM1, PRKCA, CAMK4, ATP2B4 | More | | Lanreotide | hsa04926 | Relaxin signaling pathway | 1.53E-02 | 6 | P25963, P42338, P62873, P50151, P49767, P17252 | NFKBIA, PIK3CB, GNB1, GNG10, VEGFC, PRKCA | More | | Lanreotide | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.75E-02 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | | Lanreotide | hsa04932 | Non-alcoholic fatty liver disease | 2.90E-05 | 11 | P49841, O43521, P18848, O75460, Q12933, P01584, P13073, P12074, O15239, Q16718, O14521 | GSK3B, BCL2L11, ATF4, ERN1, TRAF2, IL1B, COX4I1, COX6A1, NDUFA1, NDUFA5, SDHD | More | | Lanreotide | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.11E-03 | 7 | Q13485, P42224, P10415, P42338, P49767, P17252, P19174 | SMAD4, STAT1, BCL2, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Lanreotide | hsa04934 | Cushing syndrome | 6.07E-03 | 4 | Q99941, Q08828, O15169, Q13557 | CREBL1, ADCY1, AXIN1, CAMK2D | More | | Lanreotide | hsa04964 | Proximal tubule bicarbonate reclamation | 3.18E-04 | 2 | P00918, P49448 | CA2, GLUD2 | More | | Lanreotide | hsa04966 | Collecting duct acid secretion | 2.17E-03 | 1 | P00918 | CA2 | More | | Lanreotide | hsa04970 | Salivary secretion | 3.55E-02 | 3 | P23634, P17252, P0DP23 | ATP2B4, PRKCA, CALM1 | More | | Lanreotide | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | Lanreotide | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Lanreotide | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Lanreotide | hsa05010 | Alzheimer disease | 9.91E-04 | 13 | Q92542, O15239, P05496, P13073, P12074, O75460, P0DP24, P01584, Q12933, P18848, O15169, P05141, P43686 | NCSTN, NDUFA1, ATP5G1, COX4I1, COX6A1, ERN1, CALM2, IL1B, TRAF2, ATF4, AXIN1, SLC25A5, PSMC4 | More | | Lanreotide | hsa05012 | Parkinson disease | 3.80E-03 | 11 | P62987, O15239, P13073, P12074, P05496, P05141, O75460, P18848, P43686, P0DP24, Q13557 | UBA52, NDUFA1, COX4I1, COX6A1, ATP5G1, SLC25A5, ERN1, ATF4, PSMC4, CALM2, CAMK2D | More | | Lanreotide | hsa05014 | Amyotrophic lateral sclerosis | 3.90E-03 | 14 | O15399, P10415, O15239, P12074, P05496, Q13509, P68371, Q12933, P43686, Q53GS7, P37198, P35658, P63261, Q9GZY0 | GRIN2D, BCL2, NDUFA1, COX6A1, ATP5G1, TUBB3, TUBB2C, TRAF2, PSMC4, GLE1, NUP62, NUP214, ACTG1, NXF2; NXF2B | More | | Lanreotide | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | Lanreotide | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | | Lanreotide | hsa05020 | Prion disease | 1.44E-04 | 13 | P01584, P46531, O15239, Q16718, O14521, P05496, P12074, Q92736, P43686, O60282, P49841, Q99941, Q16539 | IL1B, NOTCH1, NDUFA1, NDUFA5, SDHD, ATP5G1, COX6A1, RYR2, PSMC4, KIF5C, GSK3B, CREBL1, MAPK14 | More | | Lanreotide | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.73E-05 | 21 | P49841, O15239, Q16718, O14521, P13073, P12074, P05496, O75460, P18848, Q12933, Q13561, P05141, P20333, Q16539, O15169, P01584, Q08752, P0DP24, Q13557, P62987, P43686 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, COX6A1, ATP5G1, ERN1, ATF4, TRAF2, DCTN2, SLC25A5, TNFRSF1B, MAPK14, AXIN1, IL1B, PPID, CALM2, CAMK2D, UBA52, PSMC4 | More | | Lanreotide | hsa05031 | Amphetamine addiction | 1.49E-02 | 4 | O15399, P0DP23, Q16566, P17252 | GRIN2D, CALM1, CAMK4, PRKCA | More | | Lanreotide | hsa05032 | Morphine addiction | 1.24E-02 | 5 | P62873, P50151, Q13370, P17252, P43250 | GNB1, GNG10, PDE3B, PRKCA, GRK6 | More | | Lanreotide | hsa05034 | Alcoholism | 4.54E-02 | 2 | P62807, O60814 | HIST1H2BC, H2BC12 | More | | Lanreotide | hsa05110 | Vibrio cholerae infection | 3.15E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | Lanreotide | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | Lanreotide | hsa05132 | Salmonella infection | 1.08E-02 | 8 | Q9UJU2, P63261, O00471, Q13489, P10415, O60282, Q13509, P68371 | LEF1, ACTG1, EXOC5, BIRC3, BCL2, KIF5C, TUBB3, TUBB2C | More | | Lanreotide | hsa05133 | Pertussis | 3.22E-04 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Lanreotide | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Lanreotide | hsa05140 | Leishmaniasis | 1.31E-02 | 7 | P13612, O75015, P13765, O60603, P01375, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MAPK14, NCF4 | More | | Lanreotide | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Lanreotide | hsa05144 | Malaria | 1.12E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Lanreotide | hsa05145 | Toxoplasmosis | 3.45E-02 | 6 | P25963, Q13489, P42224, P09917, Q13751, P11142 | NFKBIA, BIRC3, STAT1, ALOX5, LAMB3, HSPA8 | More | | Lanreotide | hsa05146 | Amoebiasis | 2.32E-04 | 9 | P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | | Lanreotide | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Lanreotide | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | Lanreotide | hsa05163 | Human cytomegalovirus infection | 8.12E-05 | 15 | P42338, P01375, P25963, P62873, P63218, P50151, P0DP23, P49841, P14778, P17252, P25025, Q16539, O00463, P30101, P01568 | PIK3CB, TNF, NFKBIA, GNB1, GNG5, GNG10, CALM1, GSK3B, IL1R1, PRKCA, CXCR2, MAPK14, TRAF5, PDIA3, IFNA21 | More | | Lanreotide | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.56E-03 | 9 | P01568, P42224, P25963, P42338, P40189, P62873, P50151, P19174, P0DP23 | IFNA21, STAT1, NFKBIA, PIK3CB, IL6ST, GNB1, GNG10, PLCG1, CALM1 | More | | Lanreotide | hsa05168 | Herpes simplex virus 1 infection | 4.24E-04 | 16 | Q9UKJ0, P25963, P01568, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13489, P30101, P42338, Q13398, Q03923, O75820, Q9UDV6, P10415 | PILRB, NFKBIA, IFNA21, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, PIK3CB, ZNF211, ZNF85, ZNF189, ZNF212, BCL2 | More | | Lanreotide | hsa05169 | Epstein-Barr virus infection | 4.35E-04 | 13 | P13765, P01106, Q13547, P04637, O00463, P10415, P07948, Q13761, P24522, P29728, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TP53, TRAF5, BCL2, LYN, RUNX3, GADD45A, OAS2, CD3E, CD3G, CD247 | More | | Lanreotide | hsa05170 | Human immunodeficiency virus 1 infection | 7.66E-03 | 10 | P42338, P62873, P50151, P0DP23, P17252, P30101, P01568, P25963, P19174, P23528 | PIK3CB, GNB1, GNG10, CALM1, PRKCA, PDIA3, IFNA21, NFKBIA, PLCG1, CFL1 | More | | Lanreotide | hsa05171 | Coronavirus disease - COVID-19 | 3.30E-02 | 7 | P25963, P42224, P01568, P40189, P42338, P19174, P17252 | NFKBIA, STAT1, IFNA21, IL6ST, PIK3CB, PLCG1, PRKCA | More | | Lanreotide | hsa05200 | Pathways in cancer | 1.70E-06 | 31 | Q13751, P42338, P08238, P42224, P25963, P19174, P04637, Q9UJU2, P17252, Q09472, P43246, Q13485, P10826, P14923, P10415, Q13489, Q13077, P49767, P14921, P25116, P62873, P50151, O95267, P78417, P24522, O75293, P0DP23, P01568, P14784, P40189, P16871 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, TP53, LEF1, PRKCA, EP300, MSH2, SMAD4, RARB, JUP, BCL2, BIRC3, TRAF1, VEGFC, ETS1, F2R, GNB1, GNG10, RASGRP1, GSTO1, GADD45A, GADD45B, CALM1, IFNA21, IL2RB, IL6ST, IL7R | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.705 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.802 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | P32248 | CCR7 | C-C chemokine receptor type 7 | P04637 | TP53 | Cellular tumor antigen p53 | 0.77 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.813 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q09472 | EP300 | Histone acetyltransferase p300 | -0.791 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.925 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P10826 | RARB | Retinoic acid receptor beta | 0.779 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14923 | JUP | Junction plakoglobin | -0.716 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P32248 | CCR7 | C-C chemokine receptor type 7 | P14923 | JUP | Junction plakoglobin | 0.711 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P32248 | CCR7 | C-C chemokine receptor type 7 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.748 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.747 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.748 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.871 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14921 | ETS1 | Protein C-ets-1 | 0.731 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | P32248 | CCR7 | C-C chemokine receptor type 7 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.792 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.703 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | P32248 | CCR7 | C-C chemokine receptor type 7 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.862 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.919 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.926 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.865 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.748 | P32248 | CCR7 | C-C chemokine receptor type 7 | P16871 | IL7R | Interleukin-7 receptor subunit alpha | 0.743 |
| Lanreotide | hsa05202 | Transcriptional misregulation in cancer | 1.45E-07 | 21 | Q12778, Q15532, P41732, P14780, P27930, P14923, Q16548, Q13489, Q13077, O15550, P04637, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, UTX, TP53, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q12778 | FOXO1 | Forkhead box protein O1 | -0.769 | P22748 | CA4 | Carbonic anhydrase 4 | Q15532 | SS18 | Protein SSXT | -0.862 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q15532 | SS18 | Protein SSXT | -0.803 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q15532 | SS18 | Protein SSXT | 0.804 | P22748 | CA4 | Carbonic anhydrase 4 | P41732 | TSPAN7 | Tetraspanin-7 | 0.706 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P41732 | TSPAN7 | Tetraspanin-7 | 0.775 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P41732 | TSPAN7 | Tetraspanin-7 | 0.703 | P22748 | CA4 | Carbonic anhydrase 4 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.925 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.861 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.942 | P22748 | CA4 | Carbonic anhydrase 4 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.708 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.734 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.924 | P22748 | CA4 | Carbonic anhydrase 4 | P14923 | JUP | Junction plakoglobin | -0.772 | P32248 | CCR7 | C-C chemokine receptor type 7 | P14923 | JUP | Junction plakoglobin | 0.711 | P22748 | CA4 | Carbonic anhydrase 4 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.833 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.837 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.913 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.797 | P22748 | CA4 | Carbonic anhydrase 4 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.718 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.748 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.712 | P22748 | CA4 | Carbonic anhydrase 4 | O15550 | UTX | Lysine-specific demethylase 6A | 0.714 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O15550 | UTX | Lysine-specific demethylase 6A | 0.789 | P32248 | CCR7 | C-C chemokine receptor type 7 | O15550 | UTX | Lysine-specific demethylase 6A | -0.715 | P32248 | CCR7 | C-C chemokine receptor type 7 | P04637 | TP53 | Cellular tumor antigen p53 | 0.77 | P22748 | CA4 | Carbonic anhydrase 4 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.834 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.779 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | P22748 | CA4 | Carbonic anhydrase 4 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.834 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.779 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | P22748 | CA4 | Carbonic anhydrase 4 | P05164 | MPO | Myeloperoxidase | 0.826 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P05164 | MPO | Myeloperoxidase | 0.805 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P05164 | MPO | Myeloperoxidase | 0.711 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P12838 | DEFA4 | Neutrophil defensin 4 | 0.767 | P22748 | CA4 | Carbonic anhydrase 4 | P08246 | ELA2 | Neutrophil elastase | 0.921 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.846 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.703 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.808 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.72 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.765 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.9 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q13547 | HDAC1 | Histone deacetylase 1 | -0.742 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Q92769 | HDAC2 | Histone deacetylase 2 | -0.746 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P12980 | LYL1 | Protein lyl-1 | 0.782 | P22748 | CA4 | Carbonic anhydrase 4 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.769 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.764 | P32248 | CCR7 | C-C chemokine receptor type 7 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.862 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.801 |
| Lanreotide | hsa05203 | Viral carcinogenesis | 2.13E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Lanreotide | hsa05210 | Colorectal cancer | 2.41E-02 | 4 | P10415, P04637, Q9UJU2, P24522 | BCL2, TP53, LEF1, GADD45A | More | | Lanreotide | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | Lanreotide | hsa05213 | Endometrial cancer | 1.91E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Lanreotide | hsa05214 | Glioma | 2.67E-04 | 6 | P0DP23, Q16566, P17252, P42338, P19174, O75293 | CALM1, CAMK4, PRKCA, PIK3CB, PLCG1, GADD45B | More | | Lanreotide | hsa05215 | Prostate cancer | 1.94E-02 | 4 | P10415, Q9UJU2, Q09472, P04637 | BCL2, LEF1, EP300, TP53 | More | | Lanreotide | hsa05216 | Thyroid cancer | 5.28E-03 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Lanreotide | hsa05217 | Basal cell carcinoma | 1.34E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Lanreotide | hsa05222 | Small cell lung cancer | 6.47E-04 | 10 | P10826, P42338, Q13751, Q13489, P10415, P25963, Q13077, P04637, P24522, O75293 | RARB, PIK3CB, LAMB3, BIRC3, BCL2, NFKBIA, TRAF1, TP53, GADD45A, GADD45B | More | | Lanreotide | hsa05223 | Non-small cell lung cancer | 4.91E-03 | 5 | P17252, P42338, P19174, P10826, O75293 | PRKCA, PIK3CB, PLCG1, RARB, GADD45B | More | | Lanreotide | hsa05224 | Breast cancer | 4.32E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Lanreotide | hsa05226 | Gastric cancer | 8.86E-03 | 5 | Q9UJU2, P04637, P24522, P14923, P10415 | LEF1, TP53, GADD45A, JUP, BCL2 | More | | Lanreotide | hsa05230 | Central carbon metabolism in cancer | 4.04E-02 | 2 | P07195, P04637 | LDHB, TP53 | More | | Lanreotide | hsa05231 | Choline metabolism in cancer | 4.91E-03 | 5 | P42338, Q9Y259, P19174, P23743, P17252 | PIK3CB, CHKB, PLCG1, DGKA, PRKCA | More | | Lanreotide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.73E-03 | 6 | P07766, P20963, P09693, P06239, Q04759, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, CD4 | More | | Lanreotide | hsa05321 | Inflammatory bowel disease | 2.42E-04 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Lanreotide | hsa05322 | Systemic lupus erythematosus | 2.93E-02 | 2 | P62807, O60814 | HIST1H2BC, H2BC12 | More | | Lanreotide | hsa05332 | Graft-versus-host disease | 8.51E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Lanreotide | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Lanreotide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 2.17E-03 | 1 | P54284 | CACNB3 | More | | Lanreotide | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Lanreotide | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Lanreotide | hsa05418 | Fluid shear stress and atherosclerosis | 1.48E-05 | 12 | Q16539, Q14145, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, KEAP1, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |